07AUG20 human skin microscopy histology cross section-1
Discovery Capabilities

​Efficacy, Safety & ADME

Predictive Drug Discovery Services

The Human Tissue Experts

Human tissue testing is a translational approach to drug discovery that bridges the gap between animal studies and clinical trials — increasing clinical success rates and adding commercial value to preclinical drug assets through proof of concept in patient-derived living tissues.

At REPROCELL we can access a wide range of human fresh, functional, intact tissues that allow accurate prediction of human safety, efficacy and bioavailability in ethically-sourced healthy and diseased tissues. Our 24/7 global tissue network and GLP lab operation is unique within the Pharma industry, allowing unrivalled access to human functional tissues and customized fee-for-service contract research. 

Many of our clients have successfully published data generated in our human tissue assays. Some clients have even managed to rescue their compounds from clinical failure, by using  human tissues from the target patient population to explore the causes of adverse effects, allowing them to identify suitable mitigation strategies.

We can also provide species comparative studies to explore differences between human and animal responses, as animal models often don't reflect human biology. You can view our catalogue and some of our client case studies below.

Browse our assay catalog  

REPROCELL is home to the world's first and largest human fresh tissue assay catalog. In this digital platform, you can filter our assays by tissue type, endpoint, receptor, platform technology, drug type, and more.

Visit the catalog →

screencapture-reprocell-predictive-drug-discovery-services-assay-catalog-2021-05-27-10_32_51

Inflammatory Bowel Disease

REPROCELL-04.06.18_0296-1
 

Skin Disease

Researcher creating biopsies from human fresh skin
 

Species Comparisons

REPROCELL-04.06.18_0026
 

Respiratory

REPROCELL-04.06.18_0460 (1)
 

Improve Clinical Success

REPROCELL can help you reduce the risks of clinical failure via our assays in human fresh tissues. Human tissue testing gives an accurate indication of human safety (including to GLP), efficacy, and bioavailability in advance of expensive clinical trials.

This invaluable information allows you to make ‘go’ or ‘no-go’ decisions with greater confidence, based on human data generated in tissues sourced from the target patient population.

Our expertise in all areas of human tissue testing – including ethics, sourcing, handling and fee-for-service experiments in human fresh tissue – allows us to act as your “Human Tissue Research Department”.

Achieve Regulatory Approval

Human tissue testing is being increasingly recognised for its translatability. As a result, the regulators encourage the use of human tissue testing in safety assessment.

When the International Partnership for Microbicides (IPM) approached the EMA for approval of an intravaginal drug-eluting ring to reduce the incidence of HIV transmission, additional data was requested to investigate the potential effects on surrounding organs.

Our scientists designed and conducted a study in human fresh uterine tissue, measuring the effects of the drug on uterine contractility. No effect on uterine contractility was observed ex vivo, which contributed to the safety assessment process, and in 2020, the ring received regulatory approval in Europe.

Lindsey and Amna looking down microscope in Biopta lab

Avoid Species Differences 

Preclinical models remain over-reliant on animals and simple cell culture systems. Although many biological pathways are conserved across species, significant differences in drug response, drug metabolism and drug absorption exist between animals and humans.

Predictive preclinical assays in fresh, intact human tissues avoids species differences, providing a more accurate prediction of the likely responses of patients during clinical trials. Moreover, the advent of precision medicine is driving the need for human-relevant predictions of drug efficacy, to better understand drug effects in patient sub-populations much earlier in drug development. 

Read our case study on Amgen's publication, which highlights the useful comparisons that can be made between matched tissues from preclinical species and humans.The species comparison studies allowed identification of the receptors involved in the adverse effects observed in the clinic and underpinned a risk mitigation strategy to counteract side-effects. 

REPROCELL-04.06.18_0076

Eliminate Clinical Adverse Effects

Adverse effects may go undetected during preclinical safety assessments and only become apparent during clinical trials. In most cases, such adverse effects in humans were not observed in animal models.

At Reprocell, we investigate adverse effects using human fresh tissues to better understand mechanisms of action and identify mitigation strategies.

REPROCELL-04.06.18_0287-1


Have questions about our human fresh tissue assays? Contact our scientists by filling in the form below.